Article

Contrasting Roles for Dopamine D1 and D2 Receptor Subtypes in the Dorsomedial Striatum but Not the Nucleus Accumbens Core during Behavioral Inhibition in the Stop-Signal Task in Rats

Behavioral and Clinical Neuroscience Institute and Department of Experimental Psychology, University of Cambridge, Cambridge CB2 3EB, United Kingdom.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.75). 05/2011; 31(20):7349-56. DOI: 10.1523/JNEUROSCI.6182-10.2011
Source: PubMed

ABSTRACT Dopamine and dopamine-receptor function are often implicated in behavioral inhibition, and deficiencies within behavioral inhibition processes linked to attention deficit/hyperactivity disorder (ADHD), schizophrenia, obsessive-compulsive disorder, and drug addiction. In the stop-signal task, which measures the speed of the process of inhibition [stop-signal reaction time (SSRT)], psychostimulant-related improvement of SSRT in ADHD is linked with dopamine function. However, the precise nature of dopaminergic control over SSRT remains unclear. This study examined region- and receptor-specific modulation of SSRT in the rat using direct infusions of the dopamine D1 receptor (DRD1) antagonist SCH 23390 or dopamine D2 receptor (DRD2) antagonist sulpiride into the dorsomedial striatum (DMStr) or nucleus accumbens core (NAcbC). DRD1 and DRD2 antagonists had contrasting effects on SSRT that were specific to the DMStr. SCH 23390 decreased SSRT with little effect on the go response. Conversely, sulpiride increased SSRT but also increased go-trial reaction time and reduced trial completion at the highest doses. These results suggest that DRD1 and DRD2 function within the DMStr, but not the NAcbC, may act to balance behavioral inhibition in a manner that is independent of behavioral activation.

Download full-text

Full-text

Available from: Adam Mar, Jul 15, 2015
0 Followers
 · 
88 Views
  • Source
    • "There are several reasons to suspect that an RI paradigm could provide a quantifiable measure of risk for ICD development . For instance, D2 dopamine receptors are specifically implicated in RI (Colzato, van den Wildenberg, & Hommel, 2013; Colzato, van den Wildenberg, Van der Does, & Hommel, 2010; Eagle et al., 2011; Ghahremani et al., 2012; Hamidovic, Dlugos, Skol, Palmer, & de Wit, 2009; Nandam et al., 2013) and are a common target of several routinely prescribed DA medications known to cause ICDs. Second, RI is impaired in pathological gamblers and individuals with an ICD manifesting as Tourette syndrome (Goudriaan, Oosterlaan, de Beurs, & van den Brink, 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's disease (Pd) is the second most prevalent degenerative neurological condition worldwide. Improving and sustaining quality of life is an important goal for Parkinson's patients. Key areas of focus to achieve this goal include earlier diagnosis and individualized treatment. In this review the authors discuss impulse control in Pd and examine how measures of impulse control from a response inhibition task may provide clinically useful information (a) within an objective test battery to aid earlier diagnosis of Pd and (b) in postdiagnostic Pd, to better identify individuals at risk of developing impulse control disorders with dopaminergic medication.
    Journal of Motor Behavior 01/2015; 47(1):29-45. DOI:10.1080/00222895.2014.941784 · 1.41 Impact Factor
  • Source
    • "In addition, our results can be linked to the findings of Chermahini and Hommel (2010) who showed that spontaneous eye-blink rates were associated with performance on the AUT, but not on the RAT. Given that spontaneous eye-blink rate is a marker of central dopaminergic functioning, and that inhibition is thought to rely predominantly on dopaminergic activity (Eagle et al., 2011), this divergence in performance also supports the role of inhibition in idea generation. "
    Cognition 01/2015; · 3.63 Impact Factor
  • Source
    • "Although in bipolar patients there was no significant difference in SSRT or post-canceled slowing between those patients who were and were not taking antipsychotics, we know from the rodent literature that D1 and D2 antagonists injected into the striatum affects SSRT. D1 antagonists reduce SSRT, and D2 antagonists prolong SSRT (Eagle et al., 2011). Although the therapeutic effect of antipsychotic medications is attributed to D2 receptor blockade, commonly prescribed antipsychotic medications also have, to varying degrees, affinity for D1 receptors (see Miller (2009) for a review) and the ratio of D1:D2 occupancy varies widely across different atypical antipsychotic drugs (Tauscher et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the present study was to compare two components of executive functioning, response monitoring and inhibition in bipolar disorder (BP) and schizophrenia (SZ). The saccadic countermanding task is a translational paradigm optimized for detecting subtle abnormalities in response monitoring and response inhibition. We have previously reported countermanding performance abnormalities in SZ, but the degree to which these impairments are shared by other psychotic disorders is unknown. 18 BP, 17 SZ, and 16 demographically-matched healthy controls (HC) participated in a saccadic countermanding task. Performance on the countermanding task is approximated as a race between movement generation and inhibition processes; this model provides an estimate of the time needed to cancel a planned movement. Response monitoring was assessed by the reaction time (RT) adjustments based on trial history. Like SZ patients, BP patients needed more time to cancel a planned movement. The two patient groups had equivalent inhibition efficiency. On trial history-based RT adjustments, however, we found a trend towards exaggerated trial history-based slowing in SZ compared to BP. Findings have implications for understanding the neurobiology of cognitive control, for defining the etiological overlap between schizophrenia and bipolar disorder and for developing pharmacological treatments of cognitive impairments.
    Psychiatry Research 12/2014; 225(3). DOI:10.1016/j.psychres.2014.12.033 · 2.68 Impact Factor
Show more